Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Helix Biopharma Corp (HBPCF)

Helix Biopharma Corp (HBPCF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Helix Biopharma Corp 2704 401 Bay Street Toronto A6 M5H 2Y4 CAN

www.helixbiopharma.com P: 905-841-2300

Description:

Helix BioPharma Corp. is an immuno-oncology company specializing in the field of cancer therapy. Its primary drug candidate is L-DOS47, which is intended for the treatment of inoperable, locally advanced, recurrent, or metastatic non-small cell lung cancer. The Company's product development initiatives are focused primarily on technologies that modulate the tumor microenvironment. It's technology platform, DOS47 yielded approximately two drug product candidates, L-DOS47 and vDOS47. L-DOS47 is an antibody protein conjugate where the urease component enzymatically converts naturally occurring urea to ammonia. L-DOS47 is under clinical study for the treatment of non-small cell lung cancer (NSCLC). L-DOS47 has completed preclinical testing and manufacturing development, following which, regulatory approvals are obtained in Poland and the United States to conduct Phase I/II and Phase I clinical studies. V-DOS47 is an antibody DOS47 conjugate that targets the vascular endothelial growth factor 2 receptor (VEGFR2).

Key Statistics

Overview:

Market Capitalization, $K 38,016
Enterprise Value, $K 37,416
Shares Outstanding, K 245,108
Annual Sales, $ 0 K
Annual Net Income, $ -4,690 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -1,350 K
EBIT, $ -4,540 K
EBITDA, $ -4,530 K
60-Month Beta 0.00
% of Insider Shareholders 7.60%
% of Institutional Shareholders 0.00%
Float, K 226,480
% Float 92.40%
Short Volume Ratio 1.00

Growth:

1-Year Return -6.68%
3-Year Return 0.00%
5-Year Return 0.00%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 71.43%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.00 on 06/14/24
Next Earnings Date 10/25/24
Earnings Per Share ttm -0.02
EPS Growth vs. Prev Year 100.00%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-5 on 08/16/24

HBPCF Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % -558.90%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share 0.00
Interest Coverage -468.00
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar